{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:58:34Z","timestamp":1790269114797,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.intimp.2022.108698","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T15:40:31Z","timestamp":1647531631000},"page":"108698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Immunotherapy of inflammatory bowel disease (IBD) through mesenchymal stem cells"],"prefix":"10.1016","volume":"107","author":[{"given":"Huldani","family":"Huldani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ria","family":"Margiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawad","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jade Catalan","family":"Opulencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Javed","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry Olegovich","family":"Bokov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nargiza N.","family":"Abdullaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homayoon","family":"Siahmansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2022.108698_b0005","first-page":"263","article-title":"European Crohn\u2019s and Colitis Organisation topical review on IBD in the elderly","volume":"11","author":"Sturm","year":"2017","journal-title":"J. Crohn's Colitis"},{"issue":"2","key":"10.1016\/j.intimp.2022.108698_b0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.25122\/jml-2018-0075","article-title":"A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease","volume":"12","author":"Seyedian","year":"2019","journal-title":"J. Med. Life"},{"issue":"2","key":"10.1016\/j.intimp.2022.108698_b0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MEG.0000000000000761","article-title":"The natural history of Crohn\u2019s disease in children: a review of population-based studies","volume":"29","author":"Duricova","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108698_b0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/diagnostics9030077","article-title":"Prevalence of oral lesions and correlation with intestinal symptoms of inflammatory bowel disease: a systematic review","volume":"9","author":"Lauritano","year":"2019","journal-title":"Diagnostics"},{"issue":"2","key":"10.1016\/j.intimp.2022.108698_b0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.disamonth.2017.07.001","article-title":"A comprehensive review and update on Crohn's disease","volume":"64","author":"Gajendran","year":"2018","journal-title":"Dis. Mon."},{"key":"10.1016\/j.intimp.2022.108698_b0030","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/S0399-8320(09)73150-1","article-title":"Environmental risk factors in Crohn's disease and ulcerative colitis: an update","volume":"33","author":"Carbonnel","year":"2009","journal-title":"Gastroenterol. Clin. Biol."},{"issue":"4","key":"10.1016\/j.intimp.2022.108698_b0035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","article-title":"Epidemiology and risk factors for IBD","volume":"12","author":"Ananthakrishnan","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108698_b0040","first-page":"247","article-title":"Inflammatory bowel disease part I: ulcerative colitis-pathophysiology and conventional and alternative treatment options","volume":"8","author":"Colitis-Pathophysiology","year":"2003","journal-title":"Altern. Med. Rev."},{"issue":"9","key":"10.1016\/j.intimp.2022.108698_b0045","first-page":"1323","article-title":"Ulcerative colitis: diagnosis and treatment","volume":"76","author":"Langan","year":"2007","journal-title":"Am. Fam. Phys."},{"issue":"3","key":"10.1016\/j.intimp.2022.108698_b0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.MIB.0000217770.21261.ce","article-title":"Risk factors for ulcerative colitis\u2013associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study","volume":"12","author":"Lakatos","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.intimp.2022.108698_b0055","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0065-2776(08)60848-2","article-title":"Alterations of the immune system in ulcerative colitis and Crohn's disease","volume":"42","author":"Macdermott","year":"1988","journal-title":"Adv. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2022.108698_b0060","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1023\/A:1020583306627","article-title":"Chemokines in the inflammatory bowel diseases","volume":"19","author":"MacDermott","year":"1999","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.intimp.2022.108698_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MIB.0000000000000384","article-title":"Monocyte and M1 macrophage-induced barrier defect contributes to chronic intestinal inflammation in IBD","author":"Lissner","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"issue":"6","key":"10.1016\/j.intimp.2022.108698_b0070","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/01.mog.0000182862.88798.28","article-title":"Oral tolerance and inflammatory bowel disease","volume":"21","author":"Kraus","year":"2005","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"7","key":"10.1016\/j.intimp.2022.108698_b0075","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1053\/j.gastro.2004.03.076","article-title":"Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease","volume":"126","author":"Kraus","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.intimp.2022.108698_b0080","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/01.MIB.0000200343.61707.52","article-title":"Evidence for a genetic defect in oral tolerance induction in inflammatory bowel disease","volume":"12","author":"Kraus","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"issue":"2","key":"10.1016\/j.intimp.2022.108698_b0085","doi-asserted-by":"crossref","first-page":"910","DOI":"10.4049\/jimmunol.155.2.910","article-title":"Induction of oral tolerance to myelin basic protein in CD8-depleted mice: both CD4+ and CD8+ cells mediate active suppression","volume":"155","author":"Chen","year":"1995","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108698_b0090","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1189\/jlb.1105696","article-title":"Aggravation of intestinal inflammation by depletion\/deficiency of \u03b3\u03b4 T cells in different types of IBD animal models","volume":"81","author":"K\u00fchl","year":"2007","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108698_b0095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/vaccines4010005","article-title":"Integrating immunologic signaling networks: the JAK\/STAT pathway in colitis and colitis-associated cancer","volume":"4","author":"Zundler","year":"2016","journal-title":"Vaccines"},{"issue":"4","key":"10.1016\/j.intimp.2022.108698_b0100","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00535-017-1401-7","article-title":"Clinical importance of IL-22 cascade in IBD","volume":"53","author":"Mizoguchi","year":"2018","journal-title":"J. Gastroenterol."},{"issue":"7","key":"10.1016\/j.intimp.2022.108698_b0105","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00210-014-0985-1","article-title":"The role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases","volume":"387","author":"Piechota-Polanczyk","year":"2014","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.intimp.2022.108698_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/4535194","article-title":"Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies","volume":"2017","author":"Tian","year":"2017","journal-title":"Oxid. Med. Cell. Longevity"},{"issue":"2","key":"10.1016\/j.intimp.2022.108698_b0115","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2478\/s11535-008-0005-x","article-title":"Molecular evidences on the benefit of N-acetylcysteine in experimental colitis","volume":"3","author":"Ebrahimi","year":"2008","journal-title":"Open Life Sci."},{"issue":"1\u20133","key":"10.1016\/j.intimp.2022.108698_b0120","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejphar.2010.08.046","article-title":"Berberine ameliorates TNBS-induced colitis by inhibiting lipid peroxidation, enterobacterial growth and NF-\u03baB activation","volume":"648","author":"Lee","year":"2010","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108698_b0125","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF01965001","article-title":"Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid","volume":"18","author":"Peskar","year":"1986","journal-title":"Agents Actions"},{"issue":"6","key":"10.1016\/j.intimp.2022.108698_b0130","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/gutjnl-2016-313535","article-title":"CD177+ neutrophils as functionally activated neutrophils negatively regulate IBD","volume":"67","author":"Zhou","year":"2018","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.intimp.2022.108698_b0135","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1053\/gast.2002.35393","article-title":"Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease","volume":"123","author":"Abreu","year":"2002","journal-title":"Gastroenterology"},{"issue":"41","key":"10.1016\/j.intimp.2022.108698_b0140","doi-asserted-by":"crossref","first-page":"6665","DOI":"10.3748\/wjg.v12.i41.6665","article-title":"Hematopoietic cell transplantation for Crohn\u2019s disease; is it time","volume":"12","author":"Leung","year":"2006","journal-title":"World J. Gastroenterol.: WJG"},{"issue":"4","key":"10.1016\/j.intimp.2022.108698_b0145","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.gastro.2012.06.039","article-title":"Increased levels of survivin, via association with heat shock protein 90, in mucosal T cells from patients with Crohn's disease","volume":"143","author":"de Souza","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.intimp.2022.108698_b0150","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.4049\/jimmunol.163.2.1081","article-title":"Resistance of Crohn\u2019s disease T cells to multiple apoptotic signals is associated with a Bcl-2\/Bax mucosal imbalance","volume":"163","author":"Ina","year":"1999","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2022.108698_b0155","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00109-013-1003-7","article-title":"ERK controls epithelial cell death receptor signalling and cellular FLICE-like inhibitory protein (c-FLIP) in ulcerative colitis","volume":"91","author":"Seidelin","year":"2013","journal-title":"J. Mol. Med."},{"issue":"12","key":"10.1016\/j.intimp.2022.108698_b0160","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1038\/ajg.2010.345","article-title":"A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization","volume":"105","author":"Oussalah","year":"2010","journal-title":"Off. J. Am. College Gastroenterol.| ACG."},{"issue":"7","key":"10.1016\/j.intimp.2022.108698_b0165","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/0003-4819-118-7-199304010-00009","article-title":"Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis","volume":"118","author":"Sutherland","year":"1993","journal-title":"Ann. Intern. Med."},{"issue":"9","key":"10.1016\/j.intimp.2022.108698_b0170","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"loss of response to anti-TNF treatments in Crohn\u2019s disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2022.108698_b0175","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2147\/CEG.S206970","article-title":"Patient and physician preferences for ulcerative colitis treatments in the United States","volume":"12","author":"Boeri","year":"2019","journal-title":"Clin. Experim. Gastroenterol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108698_b0180","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.cgh.2013.09.006","article-title":"Treat to target: a proposed new paradigm for the management of Crohn's disease","volume":"13","author":"Bouguen","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2022.108698_b0185","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/JIR.S65979","article-title":"Inflammatory bowel disease: clinical aspects and treatments","volume":"7","author":"Fakhoury","year":"2014","journal-title":"J. Inflammat. Res."},{"issue":"6","key":"10.1016\/j.intimp.2022.108698_b0190","article-title":"Inflammatory bowel disease: an overview of immune mechanisms and biological treatments","volume":"10","author":"Singh","year":"2019","journal-title":"Int. J. Pharm. Life Sci."},{"issue":"5","key":"10.1016\/j.intimp.2022.108698_b0195","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.3390\/ijms22052566","article-title":"The history and mystery of alveolar epithelial type II cells: focus on their physiologic and pathologic role in lung","volume":"22","author":"Ruaro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2022.108698_b0200","doi-asserted-by":"crossref","unstructured":"F. Salton, B. Ruaro, P. Confalonieri, M. Confalonieri, Epithelial\u2013Mesenchymal Transition: A Major Pathogenic Driver in Idiopathic Pulmonary Fibrosis? : Multidisciplinary Digital Publishing Institute, 2020, p. 608.","DOI":"10.3390\/medicina56110608"},{"issue":"1","key":"10.1016\/j.intimp.2022.108698_b0205","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.beha.2011.01.002","article-title":"Mesenchymal stem cells and autoimmune diseases","volume":"24","author":"Dazzi","year":"2011","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108698_b0210","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5966\/sctm.2011-0019","article-title":"Concise review: mesenchymal stem cells and translational medicine: emerging issues","volume":"1","author":"Ren","year":"2012","journal-title":"Stem Cells Translat. Med."},{"key":"10.1016\/j.intimp.2022.108698_b0215","doi-asserted-by":"crossref","first-page":"108712","DOI":"10.1016\/j.clim.2021.108712","article-title":"Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study","volume":"226","author":"Dauletova","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2022.108698_b0220","doi-asserted-by":"crossref","first-page":"108217","DOI":"10.1016\/j.intimp.2021.108217","article-title":"Immunotherapy of multisystem inflammatory syndrome in children (MIS-C) following COVID-19 through mesenchymal stem cells","volume":"101","author":"Suksatan","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2022.108698_b0225","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.intimp.2022.108698_b0230","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1634\/stemcells.2007-0524","article-title":"Human multipotent stromal cells undergo sharp transition from division to development in culture","volume":"26","author":"Larson","year":"2008","journal-title":"Stem Cells"},{"issue":"9","key":"10.1016\/j.intimp.2022.108698_b0235","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/cdd.2012.26","article-title":"Mesenchymal stem cells: a double-edged sword in regulating immune responses","volume":"19","author":"Li","year":"2012","journal-title":"Cell Death Differ."},{"issue":"7","key":"10.1016\/j.intimp.2022.108698_b0240","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1089\/dna.2005.24.458","article-title":"Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice","volume":"24","author":"Deng","year":"2005","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.intimp.2022.108698_b0245","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/1874325001105010242","article-title":"Suppl 2: adult mesenchymal stem cells and cell surface characterization-a systematic review of the literature","volume":"5","author":"Mafi","year":"2011","journal-title":"Open Orthopaed. J."},{"issue":"4","key":"10.1016\/j.intimp.2022.108698_b0250","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1002\/jcp.30038","article-title":"The mechanisms of cellular crosstalk between mesenchymal stem cells and natural killer cells: Therapeutic implications","volume":"236","author":"Moloudizargari","year":"2021","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108698_b0255","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s12015-014-9583-3","article-title":"Mesenchymal stem cells: a friend or foe in immune-mediated diseases","volume":"11","author":"Gazdic","year":"2015","journal-title":"Stem Cell Rev. Rep."},{"issue":"3","key":"10.1016\/j.intimp.2022.108698_b0260","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1089\/154732804323099190","article-title":"Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells","volume":"13","author":"Zhang","year":"2004","journal-title":"Stem Cells Dev."},{"issue":"8","key":"10.1016\/j.intimp.2022.108698_b0265","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/ecco-jcc\/jjab001","article-title":"Impairment of tissue resident mesenchymal stem cells in chronic ulcerative colitis and Crohn\u2019s disease","volume":"15","author":"Grim","year":"2021","journal-title":"J. Crohn's Colitis"},{"issue":"26","key":"10.1016\/j.intimp.2022.108698_b0270","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.3748\/wjg.v26.i26.3750","article-title":"Adipose-derived mesenchymal stem cells alleviate TNBS-induced colitis in rats by influencing intestinal epithelial cell regeneration, Wnt signaling, and T cell immunity","volume":"26","author":"Gao","year":"2020","journal-title":"World J. Gastroenterol."},{"issue":"7","key":"10.1016\/j.intimp.2022.108698_b0275","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3390\/ani11072061","article-title":"Effects of allogeneic mesenchymal stem cell transplantation in dogs with inflammatory bowel disease treated with and without corticosteroids","volume":"11","author":"Crist\u00f3bal","year":"2021","journal-title":"Animals"},{"key":"10.1016\/j.intimp.2022.108698_b0280","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3389\/fcell.2021.642948","article-title":"Cancer-preventive role of bone marrow-derived mesenchymal stem cells on colitis-associated colorectal cancer: roles of gut microbiota involved","volume":"9","author":"He","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.intimp.2022.108698_b0285","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3389\/fmed.2021.660614","article-title":"Exosomal MicroRNA-181a derived from mesenchymal stem cells improves gut microbiota composition, barrier function, and inflammatory status in an experimental colitis model","volume":"8","author":"Gu","year":"2021","journal-title":"Front. Med."},{"issue":"7","key":"10.1016\/j.intimp.2022.108698_b0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-02788-0","article-title":"IFN-\u03b3 promoted exosomes from mesenchymal stem cells to attenuate colitis via miR-125a and miR-125b","volume":"11","author":"Yang","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2022.108698_b0295","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2015.05.001","article-title":"An overview of microRNAs","volume":"87","author":"Hammond","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2022.108698_b0300","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.intimp.2022.108698_b0305","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.gde.2005.01.002","article-title":"MicroRNAs: a developing story","volume":"15","author":"Pasquinelli","year":"2005","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"8","key":"10.1016\/j.intimp.2022.108698_b0310","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1002\/jcp.30275","article-title":"Adipose-derived mesenchymal stem cell-secreted exosome alleviates dextran sulfate sodium-induced acute colitis by Treg cell induction and inflammatory cytokine reduction","volume":"236","author":"Heidari","year":"2021","journal-title":"J. Cell. Physiol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108698_b0315","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3109\/08830180903208303","article-title":"microRNAs in inflammation","volume":"28","author":"Sonkoly","year":"2009","journal-title":"Int. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108698_b0320","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2230.2008.02804.x","article-title":"MicroRNAs: novel regulators in skin inflammation","volume":"33","author":"Sonkoly","year":"2008","journal-title":"Clin. Experim. Dermatol.: Continuing Profess. Devel. (CPD)."},{"issue":"7","key":"10.1016\/j.intimp.2022.108698_b0325","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.4049\/jimmunol.1401779","article-title":"Noncanonical STAT3 activation regulates excess TGF-\u03b21 and collagen I expression in muscle of stricturing Crohn\u2019s disease","volume":"194","author":"Li","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108698_b0330","doi-asserted-by":"crossref","DOI":"10.4081\/ejh.2014.2457","article-title":"Contribution of intestinal smooth muscle to Crohn\u2019s disease fibrogenesis","author":"Severi","year":"2014","journal-title":"Eur. J. Histochem.: EJH"},{"key":"10.1016\/j.intimp.2022.108698_b0335","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2020.4679","article-title":"Extracellular vesicles derived from human placental mesenchymal stem cells alleviate experimental colitis in mice by inhibiting inflammation and oxidative stress","author":"Duan","year":"2020","journal-title":"Int. J. Mol. Med."},{"issue":"26","key":"10.1016\/j.intimp.2022.108698_b0340","doi-asserted-by":"crossref","first-page":"12204","DOI":"10.7150\/thno.47683","article-title":"Embryonic stem cell-derived mesenchymal stem cells promote colon epithelial integrity and regeneration by elevating circulating IGF-1 in colitis mice","volume":"10","author":"Xu","year":"2020","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.intimp.2022.108698_b0345","first-page":"1026","article-title":"Human placenta mesenchymal stem cells-derived extracellular vesicles regulate collagen deposition in intestinal mucosa of mice with colitis","volume":"25","author":"Liyun","year":"2021","journal-title":"Chin. J. Tissue Eng. Res."},{"key":"10.1016\/j.intimp.2022.108698_b0350","doi-asserted-by":"crossref","first-page":"120752","DOI":"10.1016\/j.biomaterials.2021.120752","article-title":"Heterospheroid formation improves therapeutic efficacy of mesenchymal stem cells in murine colitis through immunomodulation and epithelial regeneration","volume":"271","author":"Regmi","year":"2021","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.intimp.2022.108698_b0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-020-02025-7","article-title":"Mesenchymal stem cells and acellular products attenuate murine induced colitis","volume":"11","author":"Li","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.intimp.2022.108698_b0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/5527935","article-title":"Wogonin strengthens the therapeutic effects of mesenchymal stem cells in DSS-induced colitis via promoting IL-10 production","volume":"2021","author":"Wu","year":"2021","journal-title":"Oxid. Med. Cell. Longevity"},{"issue":"7","key":"10.1016\/j.intimp.2022.108698_b0365","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1007\/s10350-005-0052-6","article-title":"A phase I clinical trial of the treatment of Crohn\u2019s fistula by adipose mesenchymal stem cell transplantation","volume":"48","author":"Garc\u00eda-Olmo","year":"2005","journal-title":"Dis. Colon Rectum."},{"issue":"Supplement_1","key":"10.1016\/j.intimp.2022.108698_b0370","doi-asserted-by":"crossref","first-page":"S323","DOI":"10.1093\/ecco-jcc\/jjab076.417","article-title":"P293 Local Mesenchymal Stem Cells injection in Crohn\u2019s disease strictures: a phase I-II, open-label clinical study","volume":"15","author":"Vieujean","year":"2021","journal-title":"J. Crohn's Colitis"},{"issue":"5","key":"10.1016\/j.intimp.2022.108698_b0375","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/apt.13717","article-title":"The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn's disease - a phase 1 trial with three doses","volume":"44","author":"Dhere","year":"2016","journal-title":"Aliment Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2022.108698_b0380","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1053\/j.gastro.2015.06.014","article-title":"Allogeneic bone marrow\u2013derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn\u2019s disease","volume":"149","author":"Molendijk","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.intimp.2022.108698_b0385","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cgh.2013.06.021","article-title":"A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy","volume":"12","author":"Forbes","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108698_b0390","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/codi.15587","article-title":"Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn\u2019s disease: A case series","volume":"23","author":"Cabalzar\u2010Wondberg","year":"2021","journal-title":"Colorectal Dis."},{"issue":"5-8","key":"10.1016\/j.intimp.2022.108698_b0395","doi-asserted-by":"crossref","first-page":"151041","DOI":"10.1016\/j.ejcb.2019.04.002","article-title":"Mesenchymal stem cell therapy for the treatment of inflammatory diseases: challenges, opportunities, and future perspectives","volume":"98","author":"Regmi","year":"2019","journal-title":"Eur. J. Cell Biol."},{"issue":"0","key":"10.1016\/j.intimp.2022.108698_b0400","first-page":"0","article-title":"Methotrexate in inflammatory bowel disease: A primer for gastroenterologists","volume":"0","author":"AlAmeel","year":"2022","journal-title":"Saudi J. Gastroenterol.: Off. J. Saudi Gastroenterol. Associat."},{"issue":"5","key":"10.1016\/j.intimp.2022.108698_b0405","first-page":"S80","article-title":"Use of methotrexate in young patients with respect to the reproductive system","volume":"28","author":"Gromnica-Ihle","year":"2010","journal-title":"Clin. Experim. Rheumatol.-Incl Suppl."},{"issue":"980","key":"10.1016\/j.intimp.2022.108698_b0410","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1136\/pgmj.2006.055194","article-title":"Sulfasalazine-induced immune thrombocytopenia","volume":"83","author":"Cantarini","year":"2007","journal-title":"Postgrad. Med. J."},{"issue":"1","key":"10.1016\/j.intimp.2022.108698_b0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-8553(21)00421-0","article-title":"Sulfasalazine therapy in inflammatory bowel disease","volume":"18","author":"Das","year":"1989","journal-title":"Gastroenterol. Clin. North Am."},{"key":"10.1016\/j.intimp.2022.108698_b0420","doi-asserted-by":"crossref","first-page":"e02523","DOI":"10.7554\/eLife.02523","article-title":"Pharmacological inhibition of cystine\u2013glutamate exchange induces endoplasmic reticulum stress and ferroptosis","volume":"3","author":"Dixon","year":"2014","journal-title":"elife"},{"issue":"17","key":"10.1016\/j.intimp.2022.108698_b0425","doi-asserted-by":"crossref","first-page":"E450","DOI":"10.1503\/cmaj.200528","article-title":"Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection","volume":"192","author":"Juurlink","year":"2020","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.intimp.2022.108698_b0430","first-page":"233","article-title":"Hydroxychloroquine (Plaquenil) for recurrence prevention of Crohn's disease after curative surgery","volume":"19","author":"Louis","year":"1995","journal-title":"Gastroent\u00e9rologie clinique et biologique"},{"issue":"9","key":"10.1016\/j.intimp.2022.108698_b0435","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/rheumatology\/kez604","article-title":"Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study","volume":"59","author":"de Germay","year":"2020","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.intimp.2022.108698_b0440","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.gastro.2012.04.010","article-title":"Abatacept for Crohn's disease and ulcerative colitis","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"issue":"Supplement_1","key":"10.1016\/j.intimp.2022.108698_b0445","doi-asserted-by":"crossref","first-page":"i370","DOI":"10.1093\/ecco-jcc\/jjab232.491","article-title":"P364 Comparison of two treatment strategies in IBD: Biosimilar adalimumab (CinnoRA\u00ae) in monotherapy and in combination with azathioprine","volume":"16","author":"AlborziAvanaki","year":"2022","journal-title":"J. Crohn's Colitis"},{"key":"10.1016\/j.intimp.2022.108698_b0450","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cyto.2016.09.013","article-title":"Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?","volume":"101","author":"Chen","year":"2018","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.intimp.2022.108698_b0455","first-page":"1","article-title":"The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease","volume":"35","author":"Fousekis","year":"2022","journal-title":"Ann. Gastroenterol."},{"key":"10.1016\/j.intimp.2022.108698_b0460","article-title":"Certolizumab pegol (CDP870) for rheumatoid arthritis in adults","volume":"9","author":"Garcia","year":"2017","journal-title":"Cochrane Database System. Rev."},{"issue":"5","key":"10.1016\/j.intimp.2022.108698_b0465","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.intimp.2022.108698_b0470","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14712598.2017.1327576","article-title":"Golimumab for the treatment of ulcerative colitis","volume":"17","author":"Flamant","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2022.108698_b0475","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.intimp.2022.108698_b0480","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.2174\/13894501113146660224","article-title":"Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target","volume":"14","author":"Allocca","year":"2013","journal-title":"Curr. Drug Targets"},{"issue":"9","key":"10.1016\/j.intimp.2022.108698_b0485","first-page":"1131","article-title":"Emergence of inflammatory bowel disease during treatment with secukinumab","volume":"12","author":"Fobelo Lozano","year":"2018","journal-title":"J. Crohn's Colitis"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922001825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922001825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:39:45Z","timestamp":1761586785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922001825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":97,"alternative-id":["S1567576922001825"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108698","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy of inflammatory bowel disease (IBD) through mesenchymal stem cells","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108698","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108698"}}